Yüklüyor......
Unlocking the potential of antibody–drug conjugates for cancer therapy
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer treatments, with dozens more in preclinical and clinical development. The primary goal of ADCs is to improve the therapeutic index of antineoplastic agents by restricting their systemic delivery to cells that express the...
Kaydedildi:
| Yayımlandı: | Nat Rev Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8287784/ https://ncbi.nlm.nih.gov/pubmed/33558752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41571-021-00470-8 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|